CONNECT WITH US
HealthTech

HealthTech

STAT+: Why the latest heart drug failures should make us all more skeptical of AI hype

STAT — Health Tech logo

Published on

Add as a preferred source on Google
STAT+: Why the latest heart drug failures should make us all more skeptical of AI hype

The next time someone tells you that artificial intelligence, or any other new technology, is going to cure every disease, point them to the effort to fight heart attacks and strokes, which together are the largest killer in the developed world.

Because again and again, pharmaceutical researchers have learned the same hard lesson: technologies that were supposed to speed new medicines to patients have fallen short. Two studies presented Saturday at the annual meeting of the American Heart Association are a perfect example. A new understanding of genetics was supposed to increase the odds of success – and did anything but.

One study showed that a Novartis drug, pelacarsen, had no effect on the rate of heart attacks and strokes despite lowering a substance in the blood called lp(a), which genetics said should  reduce cardiovascular risk. Another large study, from Novo Nordisk, of an anti-inflammatory targeting a protein called IL-6 also showed no benefit. 



Source link
Related Topics:HealthTech

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.